
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
Glucagon-like Peptide-2 (GLP-2) is a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium. In experimental models of small intestinal injury and disease, administration of GLP-2 remarkably enhanced the repair, regeneration and absorptive capacity of the small intestinal mucosa. These findings aroused significant interest for the potential therapeutic use of GLP-2 in the treatment of intestinal disease and injury although the known relative instability of the peptide in the body represented a significant challenge.
At Zealand, we have applied our SIP®-technology and knowledge of peptide stabilization and produced a series of novel GLP-2 peptide analogues with enhanced stability and efficacy. One of these, ZP1848 has been selected and in pre-clinical pharmacological studies has been shown to attenuate small intestinal inflammation and enhance recovery from inflammation in an experimental model of Inflammatory Bowel Diseases (IBD).
Fill in the form below to tip a friend about this page.
When this page is updated you will be updated by e-mail.